Xtandi Combo Fails to Improve Survival in Advanced Prostate Cancer Patients in Phase 4 Study

Xtandi Combo Fails to Improve Survival in Advanced Prostate Cancer Patients in Phase 4 Study
Pfizer and Astellas Pharma announced that a Phase 4 clinical trial, investigating longer-term use of Xtandi (enzalutamide) as a combination treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), did not reach its primary goal of improved progression-free survival. The trial is concluding but data will continue to be evaluated, the companies said. Top-line results failed to show that continued treatment with

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Khalid Faidhi says:

    I’m stage 4 prostate cancer and utilizing the Xtandi medication for the past 5 months after i received the chemo therapy

    Is this mean,

    Am I, using the a treatment which add nothing to my case condition?..

Leave a Comment

Your email address will not be published. Required fields are marked *